The U.S. FDA approved on Wednesday the Flublok influenza vaccine, produced by Protein Sciences Corporation, for all adults 18 and older and has granted approval for use in individuals 50 and older under the accelerated approval process of biological products regulations.
Flublok is unique in that it is the only licensed flu vaccine on the market created using modern recombinant technology and is also 100 percent egg-free. In addition, it contains three times more active ingredients than traditional flu vaccines.
"Older adults are known to be at high risk for contracting and developing complications from influenza,” Lisa Dunkle, MD, chief medical officer of Protein Sciences, said. “Flublok has been shown to induce high antibody levels in seniors."
Protein Sciences specializes in developing vaccines and producing protein.
"We are excited with this approval," Dr. Manon Cox, MBA, president and CEO of Protein Sciences, said. "We set out to develop a better vaccine for the older population by increasing the amount of active ingredients in the vaccine. People of all ages have been calling and asking for Flublok and now it is terrific to be able to (finally) tell them that the product is approved for all adults. Flublok is a modern vaccine with particular benefits to individuals who want (need) to avoid exposure to egg proteins, gelatin, latex, formaldehyde or antibiotics as Flublok is free of all of these unnecessary and avoidable components."
Flublok is available nationwide at Passport Health locations nationwide and some pharmacies, clinics and doctor's offices.